Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News and Analysis
  • Published:

Anticancer TLR agonists on the ropes

Nature Reviews Drug Discovery volume 11, pages 503–505 (2012)Cite this article

Subjects

Toll-like receptor agonists have hit another setback with the Phase II failure of Idera's IMO-2055, but these immunotherapies may still make a comeback if appropriate combinations with vaccine antigens or anticancer drugs can be identified.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Authors
  1. Malini Guha
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guha, M. Anticancer TLR agonists on the ropes. Nat Rev Drug Discov 11, 503–505 (2012). https://doi.org/10.1038/nrd3775

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3775

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer